<?xml version='1.0' encoding='utf-8'?>
<document id="29557529"><sentence text="Clinical Pharmacokinetics and Drug-Drug Interactions of Elbasvir/Grazoprevir."><entity charOffset="65-76" id="DDI-PubMed.29557529.s1.e0" text="Grazoprevir" /></sentence><sentence text="Elbasvir and grazoprevir, in a fixed-dose combination of 50 and 100 mg, respectively, have received approval to be administered orally once daily, with or without ribavirin, for the treatment of chronic hepatitis C virus (HCV) infections"><entity charOffset="0-8" id="DDI-PubMed.29557529.s2.e0" text="Elbasvir" /><entity charOffset="13-24" id="DDI-PubMed.29557529.s2.e1" text="grazoprevir" /><entity charOffset="163-172" id="DDI-PubMed.29557529.s2.e2" text="ribavirin" /><pair ddi="false" e1="DDI-PubMed.29557529.s2.e0" e2="DDI-PubMed.29557529.s2.e0" /><pair ddi="false" e1="DDI-PubMed.29557529.s2.e0" e2="DDI-PubMed.29557529.s2.e1" /><pair ddi="false" e1="DDI-PubMed.29557529.s2.e0" e2="DDI-PubMed.29557529.s2.e2" /><pair ddi="false" e1="DDI-PubMed.29557529.s2.e1" e2="DDI-PubMed.29557529.s2.e1" /><pair ddi="false" e1="DDI-PubMed.29557529.s2.e1" e2="DDI-PubMed.29557529.s2.e2" /></sentence><sentence text=" The absorption characteristics of elbasvir and grazoprevir have been adequately summarized, although differences were observed for grazoprevir (e"><entity charOffset="35-43" id="DDI-PubMed.29557529.s3.e0" text="elbasvir" /><entity charOffset="48-59" id="DDI-PubMed.29557529.s3.e1" text="grazoprevir" /><entity charOffset="132-143" id="DDI-PubMed.29557529.s3.e2" text="grazoprevir" /><pair ddi="false" e1="DDI-PubMed.29557529.s3.e0" e2="DDI-PubMed.29557529.s3.e0" /><pair ddi="false" e1="DDI-PubMed.29557529.s3.e0" e2="DDI-PubMed.29557529.s3.e1" /><pair ddi="false" e1="DDI-PubMed.29557529.s3.e0" e2="DDI-PubMed.29557529.s3.e2" /><pair ddi="false" e1="DDI-PubMed.29557529.s3.e1" e2="DDI-PubMed.29557529.s3.e1" /><pair ddi="false" e1="DDI-PubMed.29557529.s3.e1" e2="DDI-PubMed.29557529.s3.e2" /></sentence><sentence text="g" /><sentence text=", increased exposure at steady state in patients), but not elbasvir, between healthy and HCV-infected subjects" /><sentence text=" Inconsistencies with respect to absorption were also reported on the effects of food or acid reducers (famotidine or pantoprazole) in the literature"><entity charOffset="104-114" id="DDI-PubMed.29557529.s6.e0" text="famotidine" /><entity charOffset="118-130" id="DDI-PubMed.29557529.s6.e1" text="pantoprazole" /><pair ddi="false" e1="DDI-PubMed.29557529.s6.e0" e2="DDI-PubMed.29557529.s6.e0" /><pair ddi="false" e1="DDI-PubMed.29557529.s6.e0" e2="DDI-PubMed.29557529.s6.e1" /></sentence><sentence text=" Many distribution characteristics of elbasvir and grazoprevir have been obtained from in vitro models, using incubation conditions that were in many cases inconsistent with normal physiological conditions in humans"><entity charOffset="38-46" id="DDI-PubMed.29557529.s7.e0" text="elbasvir" /><entity charOffset="51-62" id="DDI-PubMed.29557529.s7.e1" text="grazoprevir" /><pair ddi="false" e1="DDI-PubMed.29557529.s7.e0" e2="DDI-PubMed.29557529.s7.e0" /><pair ddi="false" e1="DDI-PubMed.29557529.s7.e0" e2="DDI-PubMed.29557529.s7.e1" /></sentence><sentence text=" Elbasvir and grazoprevir appear to undergo modest hepatic metabolism and are excreted primarily unchanged (~ 80% parent drug found) in feces"><entity charOffset="14-25" id="DDI-PubMed.29557529.s8.e0" text="grazoprevir" /></sentence><sentence text=" Both elbasvir and grazoprevir are substrates of cytochrome P450 (CYP) 3A4 enzyme, but mechanistic experiments were lacking to demonstrate the role of other enzymes and the precise relative % contribution of CYP3A4"><entity charOffset="6-14" id="DDI-PubMed.29557529.s9.e0" text="elbasvir" /><entity charOffset="19-30" id="DDI-PubMed.29557529.s9.e1" text="grazoprevir" /><pair ddi="false" e1="DDI-PubMed.29557529.s9.e0" e2="DDI-PubMed.29557529.s9.e0" /><pair ddi="false" e1="DDI-PubMed.29557529.s9.e0" e2="DDI-PubMed.29557529.s9.e1" /></sentence><sentence text=" The pharmacokinetics of elbasvir and grazoprevir have been characterized in various special populations (elderly, male vs"><entity charOffset="25-33" id="DDI-PubMed.29557529.s10.e0" text="elbasvir" /><entity charOffset="38-49" id="DDI-PubMed.29557529.s10.e1" text="grazoprevir" /><pair ddi="false" e1="DDI-PubMed.29557529.s10.e0" e2="DDI-PubMed.29557529.s10.e0" /><pair ddi="false" e1="DDI-PubMed.29557529.s10.e0" e2="DDI-PubMed.29557529.s10.e1" /></sentence><sentence text=" female, Caucasian vs" /><sentence text=" Asian, renal impairment, and hepatic impairment)" /><sentence text=" Other than moderate and severe hepatic impairment where administrations are contraindicated, no dose adjustments are required for both drugs in these special patient populations" /><sentence text=" The available drug-drug interaction data provided some consistency between in vitro and in vivo observations and, in some instances, can provide predictions of likely clinically relevant scenarios" /><sentence text="" /></document>